The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.
Hakan Mellstedt
Employment or Leadership Position - Kancera
Consultant or Advisory Role - Kancera
Stock Ownership - Kancera
Amir Hossein Daneshmanesh
Stock Ownership - Kancera
Ali Moshfegh
Stock Ownership - Kancera
Mohammad Hojat Farsangi
Stock Ownership - Kancera
Salam Khan
No relevant relationships to disclose
Eva Mikaelsson
No relevant relationships to disclose
Jan Vagberg
Employment or Leadership Position - Kancera
Styrbjorn Bystrom
Employment or Leadership Position - Kancera
Johan Schultz
Employment or Leadership Position - Kancera
Thomas Olin
Employment or Leadership Position - Kancera
Stock Ownership - Kancera
Anders Österborg
Consultant or Advisory Role - Kancera